AmerisourceBergen (NYSE:ABC) will announce its earnings results before the market opens on Wednesday, May 2nd. Analysts expect the company to announce earnings of $1.84 per share for the quarter. AmerisourceBergen has set its FY18 guidance at $6.45-6.65 EPS.
AmerisourceBergen (NYSE:ABC) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.20. AmerisourceBergen had a net margin of 0.66% and a return on equity of 53.65%. The company had revenue of $40.47 billion for the quarter, compared to analyst estimates of $40.42 billion. During the same quarter in the previous year, the firm posted $1.36 earnings per share. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. On average, analysts expect AmerisourceBergen to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.
NYSE ABC opened at $90.14 on Wednesday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 0.50 and a current ratio of 0.95. The company has a market capitalization of $19,741.65, a PE ratio of 15.33, a price-to-earnings-growth ratio of 1.36 and a beta of 1.06. AmerisourceBergen has a 12-month low of $71.90 and a 12-month high of $106.27.
In other news, Director Richard W. Gochnauer sold 2,278 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $101.13, for a total value of $230,374.14. Following the completion of the sale, the director now owns 13,225 shares of the company’s stock, valued at approximately $1,337,444.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert P. Mauch sold 1,000 shares of the company’s stock in a transaction on Tuesday, April 17th. The shares were sold at an average price of $90.00, for a total transaction of $90,000.00. Following the completion of the sale, the executive vice president now directly owns 13,123 shares of the company’s stock, valued at approximately $1,181,070. The disclosure for this sale can be found here. In the last three months, insiders sold 155,809 shares of company stock valued at $14,536,032. Corporate insiders own 27.30% of the company’s stock.
A number of analysts recently weighed in on ABC shares. Zacks Investment Research lowered shares of AmerisourceBergen from a “buy” rating to a “hold” rating in a report on Tuesday, March 20th. Argus upped their target price on shares of AmerisourceBergen from $93.96 to $115.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Bank of America started coverage on shares of AmerisourceBergen in a report on Tuesday, February 27th. They set a “buy” rating and a $111.00 target price on the stock. Jefferies Group set a $95.00 target price on shares of AmerisourceBergen and gave the stock a “hold” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $102.00 target price on shares of AmerisourceBergen in a report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $102.72.
ILLEGAL ACTIVITY WARNING: “AmerisourceBergen (ABC) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/25/amerisourcebergen-abc-scheduled-to-post-quarterly-earnings-on-wednesday.html.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.